Odyssey Therapeutics, Inc.
BioSniper AI · ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for autoimmune and inflammatory diseases, with lead candidate OD-001 in Phase 2a for ulcerative colitis.
Key risk: Clinical-stage dependency
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for autoimmune and inflammatory diseases, with lead candidate OD-001 in Phase 2a for ulcerative colitis.
- Reported positive clinical proof-of-concept data for OD-001, a first-in-class oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis [news · published 2026-06-17].
- Completed an upsized initial public offering of 15,500,000 shares at $18.00 per share, priced on May 7, 2026 [news · published 2026-05-08].
- Cash on hand as of March 31, 2026, together with net proceeds from the IPO and concurrent private placement, of $464M expected to fund operations into the second half of 2028 [news · published 2026-06-17].
- Insider transactions include purchases by directors and major stockholders at $18.00 per share on May 11, 2026 [insider_transaction].
What works
- Lead candidate OD-001 has shown positive clinical proof-of-concept data in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis, suggesting potential efficacy in a large autoimmune market [news · published 2026-06-17].
- Strong cash position of $464M as of March 31, 2026, including IPO and private placement proceeds, provides runway into the second half of 2028 [news · published 2026-06-17].
- The company is focused on first-in-class oral medicines targeting disease pathology, which could differentiate it from existing biologic therapies [news · published 2026-05-08].
What to weigh
- The company is a clinical-stage biopharmaceutical company with no approved products, meaning it is entirely dependent on successful clinical development and regulatory approval [news · published 2026-05-08].
- Positive Phase 2a data for OD-001 is early-stage; larger Phase 2b or Phase 3 trials will be needed to confirm efficacy and safety, with no guarantee of success [news · published 2026-06-17].
- Insider transactions show significant stock-based compensation and option exercises, which could lead to dilution for public shareholders [insider_transaction].
From the filings
Quoted directly from source documents.
Positive Phase 2a data for OD-001 in ulcerative colitis
“Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis”
News · June 17, 2026
Cash runway into second half of 2028
“Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028”
News · June 17, 2026
Upsized IPO pricing
“pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share”
News · May 8, 2026
Risks & what to watch (3)›
Key risks
- Clinical-stage dependency — No approved products; success hinges on future clinical trial outcomes and regulatory approvals [news · published 2026-05-08].
- Early-stage data uncertainty — Phase 2a proof-of-concept data for OD-001 is preliminary; larger trials needed to confirm [news · published 2026-06-17].
- Potential shareholder dilution — Insider transactions show stock option exercises and compensation, which may dilute existing shareholders [insider_transaction].
What to watch
- Initiation and results of Phase 2b or Phase 3 trials for OD-001 in ulcerative colitis [news · published 2026-06-17].
- Cash burn rate and any additional financing activities beyond the IPO [news · published 2026-06-17].
- Pipeline progress for other preclinical or clinical candidates targeting autoimmune diseases [news · published 2026-05-08].
Sources: Insider filings · News · Generated July 14, 2026 · How we verify sources →
Unlock the full Odyssey Therapeutics, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Odyssey Therapeutics, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
12.7 months
OCF -$41M · Net income -$38M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
9 buys · 3 sells (180d)
Runway
Financials
Frequently asked questions
What is the AI investment thesis for Odyssey Therapeutics, Inc.?
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for autoimmune and inflammatory diseases, with lead candidate OD-001 in Phase 2a for ulcerative colitis.
Who is the CEO of Odyssey Therapeutics, Inc.?
Dr. Gary D. Glick Ph.D. is the chief executive officer of Odyssey Therapeutics, Inc. (ODTX).
Where is Odyssey Therapeutics, Inc. headquartered?
Odyssey Therapeutics, Inc. (ODTX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Odyssey Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.